Hemostemix Stock Price, News & Analysis

Hemostemix (OTCQB: HMTXF) appointed Dr. David B. Alper as Multidisciplinary Physician Education Lead and added him to its Scientific Advisory Board, effective January 2026.

Dr. Alper will lead physician education and clinical engagement for VesCell (ACP-01) with three initiatives: clinical practice engagement in Florida, outreach to U.S. schools of podiatric medicine, and multidisciplinary professional forums focused on ischemic disease, patient selection, and procedural integration.

Hemostemix (OTCQB: HMTXF) announced that CEO Thomas Smeenk published a theoretical manuscript introducing the Conformal Consciousness Hypothesis (CCH), proposing a dimensionless invariant A = E/(hν) as a possible relational constant linking General Relativity, Quantum Mechanics, Cosmology, and String Theory.

The paper presents mathematical appendices on conformal transformations and discusses implications for Penrose's Conformal Cyclic Cosmology, non-computability, entanglement, and string vibrational modes. The company frames the work as evidence of the CEO's analytical approach applied to Hemostemix commercialization of VesCell (ACP-01) in markets including Florida, The Bahamas, and Canada. The manuscript is available at ConformalConsciousness.com.

Hemostemix (OTCQB: HMTXF) granted a total of 963,000 stock options on December 11, 2025, subject to regulatory approval.

Of the grant, 663,000 options vest immediately and 330,000 vest 50% on December 11, 2025 and 50% on December 11, 2026. All options carry an exercise price of $0.09 and expire on December 11, 2030. After issuance Hemostemix has 19,124,694 options issued and outstanding. The grant included 663,000 options to directors and officers and relied on specified exemptions under MI 61-101 for valuation and minority approval. The company noted the material change report was not filed at least 21 days prior due to timing.

Hemostemix (OTCQB: HMTXF) announced two corporate developments: the FDA scheduled a Pre-IND meeting on January 16, 2026 to review a Phase I basket clinical trial protocol for ACP-01 covering ischemia-related indications (vascular dementia, ischemic cardiomyopathy, PAD, generalized ischemia); and the company proposed a non-brokered private placement of up to $960,000 (8,000,000 common shares at $0.12), subject to TSXV approval. All securities will have a four-month hold period. Stated use of proceeds includes FDA preparations, clinical operations expansion in Florida, The Bahamas and Canada, and general working capital.

Hemostemix (OTCQB: HMTXF) appointed Shaune Harding, OStJ, RN (non-practicing) as Director of Patient Care & Clinical Operations effective December 4, 2025. Harding will oversee patient onboarding, comprehensive medical-records transfer, multi-year health-journey mapping, continuous wearable-data monitoring (e.g., Fitbit Sense 2), monthly follow-ups, and adverse-event tracking with escalation and formal reporting.

The role covers patient programs in The Bahamas, Florida, and Canada and is described as supporting long-term continuity of care, enabling patient data capture to advance regulatory approval of ACP-01/VesCell.

Hemostemix (OTCQB: HMTXF) will present at Innovations in Wound Healing 2025 in Key West, Florida, December 11-14, highlighting clinical data for its cell therapy ACP-01/VesCell in peripheral arterial disease and chronic limb-threatening ischemia (CLTI).

Key disclosed findings include published studies reporting 83% limb salvage, 0% mortality in some cohorts, and reported ulcer size reduction from a mean of 146 mm2 to 0.48 mm2 at 3 months in treated patients. The release notes ACP-01 is available in Florida under SB 1768.

Hemostemix (OTCQB: HMTXF) will attend DFCon 2025 in San Antonio to present clinical outcomes for ACP-01 (VesCell™) and meet clinicians and researchers over three days.

Phase II midpoint results as published by the University of Toronto: 0% mortality and 83% limb preservation at a 4.5-year midpoint for treated subjects; in a subgroup with ulcers (21 treated, 8 placebo) mean ulcer size fell from 146 mm2 to 0.48 mm2 (p = 0.01) by 3 months; no treatment-related complications at one year.

Financing: TSXV approved a non-brokered private placement of $518,440 adding 520,090 units to a previously closed 4,193,000 units; each unit priced at $0.11 and includes one common share plus one warrant exercisable at $0.15 for two years, with an acceleration feature triggered if the 10-day VWAP exceeds $0.185.

Hemostemix (OTCQB: HMTXF) announced a binding Letter of Intent to acquire two cardiology practices from Dr. Roberto Fernandez-de-Castro and Dr. Hector Rosario Figueroa for 2,000,000 common shares each (subject to adjustment and TSXV approval).

The two cardiologists have combined experience treating more than 200 patients with ACP-01 across multiple cardiovascular indications, and will help implement ACP-01 therapy in the Dominican Republic and the Bahamas. Hemostemix says the acquisitions create anchor practices to accelerate commercialization and future trial expansion and to generate predictable patient flow.

The TSXV approved a financing extension to December 1, 2025. To date the company raised $461,230 via 4,193,000 Units at $0.11 per Unit; each Unit includes one share and one warrant exercisable at $0.15 for two years with an accelerated expiry clause.

Hemostemix (OTCQB: HMTXF) announced on November 20, 2025 that Dr. William R. Shankle will lead a Phase I clinical trial testing ACP-01 (VesCell) as a treatment for vascular dementia (VaD). The company described ACP-01 as its autologous stem cell therapy offered to no-option patients for various ischemic and cardiac conditions.

Dr. Shankle reportedly manages about 500 individuals diagnosed with cognitive impairment and is pre-screening up to 30 patients whose condition is primarily vascular in origin for enrolment in the trial.